Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oral multivalent reassortant rotavirus attenuated live vaccine (vero cell)
- Development stage
- Preclinical
- Lead developer
- Shandong Yidu Biotechnology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Oral multivalent reassortant rotavirus attenuated live vaccine (Vero cell), also known as TAB-5101, is a live-attenuated, human-bovine reassortant rotavirus vaccine being developed by Shandong Yidu Biotechnology in collaboration with the US National Institutes of Health (NIH). The vaccine utilizes human-bovine reassortant rotavirus strains (where genes encoding the outer capsid VP7 proteins from clinically important human rotavirus serotypes are inserted into a bovine rotavirus backbone) cultivated in Vero cells. It is designed for oral administration to induce protective immunity against rotavirus gastroenteritis and rotavirus-associated diarrhea in infants and young children. The vaccine is currently in preclinical development.
- Other names
- Human-Bovine Reassortant Rotavirus VaccineMultivalent Human-Bovine Rotavirus VaccineOral Multivalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cell)五价轮状病毒减毒活疫苗五价轮状病毒减毒活疫苗(Vero细胞)口服多价重配轮状病毒减毒活疫苗(Vero细胞)
Beyond the preview
Go deeper on oral multivalent reassortant rotavirus attenuated live vaccine (vero cell).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oral multivalent reassortant rotavirus attenuated live vaccine (vero cell).